• PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?

    Oct 1, 2018, 00:00

  • CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER- MAPPING FROM EPIC TO PORPUS

    Oct 1, 2018, 00:00

  • PSY64 - BLEEDING EPISODES, THE MOST IMPACTFUL VARIABLE IN THE TREATMENT COST OF THE HEMOPHILIA A IN COLOMBIA. DATA FROM THE LITERATURE AND THE REAL LIFE

    Oct 1, 2018, 00:00

  • PHP303 - WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU?

    Oct 1, 2018, 00:00

  • PMS89 - DEVELOPMENT OF AN OUTCOMES MEASUREMENT TOOL TO EVALUATE THE QUALITY OF BIOLOGIC SWITCH IN PSORIATIC ARTHRITIS

    Oct 1, 2018, 00:00

  • PRS97 - PATIENT REPORTED OUTCOMES IN COPD CLINICAL TRIALS- TRENDS AND GAPS

    Oct 1, 2018, 00:00

  • PSY46 - A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY – THE CASE OF NOVEL TREATMENT COMBINATIONS FOR FRONTLINE TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM)

    Oct 1, 2018, 00:00

  • PMD25 - RISK FACTORS ASSOCIATED WITH PCO FOLLOWING CATARACT SURGERY- REAL-WORLD OUTCOMES STUDY IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PCN301 - HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER

    Oct 1, 2018, 00:00

  • PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANY

    Oct 1, 2018, 00:00

  • PMD14 - PDL1 TESTING PATTERNS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER IN ISRAEL - AN ANALYSIS OF REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PMU42 - ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIA

    Oct 1, 2018, 00:00

  • PMH39 - HEALTH-ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS IN PSYCHIATRIC IN-PATIENT CARE

    Oct 1, 2018, 00:00

  • PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL- IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)

    Oct 1, 2018, 00:00

  • PMD38 - CELL-FREE FETAL DNA AS A CONTINGENT PRENATAL SCREENING OF TRISOMIES CONDITIONAL TO A RISK ≥ 1-1,000 FOR ITALIAN PREGNANT WOMEN- AN ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMH49 - LAUNCHING LONG ACTING PRODUCTS TO TREAT OPIOID USE DISORDER- ARE PAYERS WILLING TO PAY PREMIUM PRICE?

    Oct 1, 2018, 00:00

  • PRM4 - A CASE STUDY IN CHOOSING WISELY RECOMMENDATION ADOPTION- SINGLE FRACTION RADIATION TREATMENT OF BONE METASTASES

    Oct 1, 2018, 00:00

  • PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES

    Oct 1, 2018, 00:00

  • PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN

    Oct 1, 2018, 00:00

  • PMD134 - MEDICAL DEVICE APPRAISAL IN THE UK- WHAT ARE THE COMMON PITFALLS OF MANUFACTURER LITERATURE REVIEWS?

    Oct 1, 2018, 00:00

  • PSY70 - MANAGEMENT COSTS OF CHEMOTHERAPY AND ALLOGENEIC STEM-CELL TRANSPLANT OF CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE

    Oct 1, 2018, 00:00

  • PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN325 - COMPARING THE ROLE OF DIFFERENT SPECIALITIES IN THE MANAGEMENT OF PROSTATE CANCER IN FRANCE AND ITALY- INSIGHTS FROM A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PCN320 - RECOMMENDATIONS OF SPANISH THERAPEUTIC POSITIONING REPORTS FOR NEW ONCOLOGY DRUGS SINCE YEAR 2013

    Oct 1, 2018, 00:00

  • PMH14 - SOCIAL FUNCTIONING AT ADMISSION IN PATIENTS WITH MENTAL ILLNESS HOSPITALIZED COMPULSORILY BY PREFECTURAL GOVERNORS IN ACCORDANCE WITH THE PROVISIONS OF ARTICLE 29 OF THE JAPANESE MENTAL HEALTH ACT.

    Oct 1, 2018, 00:00

  • PSY85 - ECONOMIC BURDEN ASSOCIATED WITH RPE65 GENE RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP11 - HOW TO RESOLVE ISSUES EXPERIENCED BY PATIENTS IN EARLY PHASE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS

    Oct 1, 2018, 00:00

  • PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017)- THE CASE OF BULGARIA

    Oct 1, 2018, 00:00

  • PCN270 - HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH 6 PREVALENT CANCER IN SPAIN, A REALWORLD DATA STUDY

    Oct 1, 2018, 00:00

  • PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATION

    Oct 1, 2018, 00:00

  • PMD30 - BUDGET IMPACT ANALYSIS OF ROUTINE ADOPTION OF NON-INVASIVE PRENATAL TESTING (NIPT) IN DIFFERENT RISK-SCORE PREGNANCY POPULATIONS IN THE UK

    Oct 1, 2018, 00:00

  • PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPT

    Oct 1, 2018, 00:00

  • PGI24 - COST-UTILITY ANALYSIS OF VITAMINE E AND PIOGLITAZONE IN ADDITION TO 2 YEARS OF LIFE-STYLE MODIFICATION THERAPY FOR NON-ALCOHOLIC STEATOHEPATITIS PATIENTS IN JAPAN

    Oct 1, 2018, 00:00

  • PRS58 - PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)- WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PND117 - PHYSICIAN REPORTED ADHERENCE IN MS PATIENTS TREATED WITH INJECTABLE PLATFORM THERAPIES VERSUS DELAYED-RELEASE DIMETHYL FUMARATE- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PCN309 - DIVERSITY IN SAFETY DATA ANALYSES IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTS

    Oct 1, 2018, 00:00

  • PRM9 - A LONGITUDINAL, ITEM-LEVEL ANALYSIS METHODOLOGY TO SUPPORT THE INTERPRETABILITY OF MULTI-ITEM PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC- COMPARISON OF VALUE TO PRICE

    Oct 1, 2018, 00:00

  • PMS101 - EVAULATION OF OUTCOMES AND PHYSIOTERAPY REHABILITATION AFTER DIRECT ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY COMPARED TO CONVENTIONAL ANTEROLATERAL APPROACH

    Oct 1, 2018, 00:00

  • PRM102 - ANALYZING REAL-WORLD DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS- A CASE STUDY IN METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PMU123 - THE RELATIONSHIP BETWEEN INDIVIDUAL-LEVEL DEPRIVATION WITH HEALTH-RELATED QUALITY OF LIFE IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PIN11 - HPV9-RELATED DISEASES- THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALY

    Oct 1, 2018, 00:00

  • PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN- NATIONWIDE RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PMD137 - CARDIAC IMPLANT REGISTRIES 2006-2016- SYSTEMATIC REVIEW OF GLOBAL PRACTICES

    Oct 1, 2018, 00:00

  • PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLAND

    Oct 1, 2018, 00:00

  • PIH46 - ANALYSING THE ATTITUDE OF OLD AGE HOME RESIDENTS ON POLYPHARMACY AND DEPRESCRIBING OF MEDICATIONS IN MANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PMS38 - COST EFFECTIVENESS ANALYSIS OF SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PIN76 - IMPACT OF TRANSFERRING ARTS DISPENSING FROM HOSPITAL TO COMMUNITY PHARMACIES- A PILOT STUDY IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD155 - IMPACT OF MINIMALLY INVASIVE TREATMENTS FOR PERIPHERAL ARTERIAL DISEASE IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN118 - THE BURDEN OF CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PHP220 - OLD DRUGS TURNED NEW FOR ULTRA ORPHAN DISEASE- A CHALLENGE FOR PAYERS OR FOR THE INDUSTRY?

    Oct 1, 2018, 00:00

  • PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS

    Oct 1, 2018, 00:00

  • PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PSS48 - PARENTS’ BELIEFS AND KNOWLEDGE ABOUT THE MANAGEMENT OF OTITIS MEDIA IN UNAIZAH, SAUDIARABIA- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATION

    Oct 1, 2018, 00:00

  • PND158 - CHANGES IN SLEEP PATTERNS AFTER VAGUS NERVE STIMULATION, DEEP BRAIN STIMULATION OR EPILEPSY SURGERY- SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • RM2 - MIXTURE METHODS INCORPORATING GENERAL POPULATION MORTALITY IN THE LIKELIHOOD FUNCTION OF PARAMETRIC DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?

    Oct 1, 2018, 00:00

  • PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSY152 - IMPACT OF FATIGUE ON RESOURCE UTILIZATION AND HEALTHCARE COSTS IN AUTOIMMUNE (AI) DISEASE

    Oct 1, 2018, 00:00

  • PSS67 - UNDERSTANDING THE PATIENT EXPERIENCE OF PRESBYOPIA AND IDENTIFICATION OF PATIENT-REPORTED OUTCOME ASSESSMENTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND125 - THE ASSOCIATION BETWEEN UTILITIES AND DISEASE SEVERITY FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP238 - CARER DISUTILITY- IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?

    Oct 1, 2018, 00:00

  • PND132 - ECONOMIC BURDEN OF MIGRAINE IN BRAZIL- RESULTS FROM MY MIGRAINE VOICE SURVEY

    Oct 1, 2018, 00:00

  • PCN36 - THE EFFECT OF INTRODUCING NIVOLUMAB IN THE ADJUVANT TREATMENT SETTING OF MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PUK1 - DR RAJA AHSAN AFTAB

    Oct 1, 2018, 00:00

  • PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMU35 - COST COMPARISON OF COMPLEMENTARY AND ALTERNATIVE MEDICINE SPECIALIZED UNIT IN SUS

    Oct 1, 2018, 00:00

  • PRM174 - OPERATING SYSTEM UPGADES DO NOT ADVERSELY AFFECT ECOA COMPLETION BEHAVIOR WHEN USING A BRING YOUR OWN DEVICE (BYOD) APP.

    Oct 1, 2018, 00:00

  • PMD159 - ASSESSMENT OF THE MARKET ACCESS POTENTIAL OF A NOVEL MEDICAL DEVICE AND APP COMBINATION FOR AN ORPHAN DISEASE

    Oct 1, 2018, 00:00

  • PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINE

    Oct 1, 2018, 00:00

  • PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?

    Oct 1, 2018, 00:00

  • PCN194 - COST-EFFECTIVENESS OF SCALING-UP CERVICAL CANCER SCREENING RATES AND HPV VACCINE INITIATION IN TURKEY

    Oct 1, 2018, 00:00

  • PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY- THE SAMANTA QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PSY215 - MEASURING QUALITY OF LIFE FOR ECONOMIC EVALUATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD) FROM CHILDHOOD TO ADULTHOOD- PROTOCOL FOR A NEW PREFERENCE-BASED MEASURE

    Oct 1, 2018, 00:00

  • PMD140 - OUT-OF-POCKET PAYMENTS FOR MEDICAL DEVICES AND EQUITY IN HEALTHCARE FOR PATIENTS WITH PRIMARY LYMPHEDEMA IN FRANCE

    Oct 1, 2018, 00:00

  • PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT- EXPERIENCES IN GERMANY 2018

    Oct 1, 2018, 00:00

  • PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PMD114 - ASSESSING AND MODELING ORGANIZATIONAL IMPACT OF TILMANOCEPT IN PERFORMING SENTINEL LYMPH NODE BIOPSY IN FRANCE

    Oct 1, 2018, 00:00

  • PCN249 - CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) AND DRIVERS OF ANTIEMETIC PRESCRIBING- RESULTS OF A QUALITATIVE IN-PRACTICE STUDY OF CLINICIANS FROM VARIOUS SETTINGS

    Oct 1, 2018, 00:00

  • PMU63 - EFFICIENCY ASSESSMENT IN PRIMARY HEALTHCARE CENTERS OF A HEALTH DISTRICT

    Oct 1, 2018, 00:00

  • PHP350 - PERFORMANCE AND OUTCOMES BASED CONTRACTS IN THE EU AND USA- COMPARISON OF TRENDS AND RECENT DEVELOPMENTS

    Oct 1, 2018, 00:00

  • PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS- SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PCN266 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BLADDER CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015- NEUROLOGICAL DISORDERS

    Oct 1, 2018, 00:00

  • PND15 - TREATMENT AND CHARACTERISTICS OF PEDIATRIC PATIENTS WITH FOCAL EPILEPSY IN GERMANY

    Oct 1, 2018, 00:00

  • PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT- A MARKER OF HTA FAILURE?

    Oct 1, 2018, 00:00

  • PDB29 - TYPE 2 DIABETES- DISCONTINUATION OF ANTIDIABETIC DRUG DISPENSING 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PCV131 - IMPACT OF TIMELY INITIATION OF ANTIHYPERTENSIVE MEDICATIONS FOR PATIENTS WITH HYPERTENSION OR ELEVATED BLOOD PRESSURE

    Oct 1, 2018, 00:00

  • PMU114 - COMPARING A DIRECT AND STAGED APPROACH TO ITEM SELECTION IN A MULTI-DIMENSIONAL PATIENT-REPORTED OUTCOME MEASURE

    Oct 1, 2018, 00:00

  • PND69 - COST-UTILITY ANALYSIS OF COMMUNITY OCCUPATIONAL THERAPY IN DEMENTIA (COTID-UK) VERSUS USUAL CARE- RESULTS FROM VALID, A MULTI-SITE RANDOMIZED CONTROLLED TRIAL IN THE UK

    Oct 1, 2018, 00:00

  • PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL

    Oct 1, 2018, 00:00

  • PHP235 - INDIRECT TREATMENT COMPARISONS (ITC) FOR HTA IN EUROPE – UNDERSTANDING REQUIREMENTS FOR INDUSTRY SUBMISSIONS

    Oct 1, 2018, 00:00

  • PSY223 - QUALITATIVE RESEARCH IN HAEMOPHILIA A- EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

    Oct 1, 2018, 00:00

  • PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5L

    Oct 1, 2018, 00:00

  • PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLAND

    Oct 1, 2018, 00:00

  • PIN56 - COST-EFFECTIVENESS OF VARICELLA AND HERPES ZOSTER VACCINATION IN THE SWEDISH POPULATION

    Oct 1, 2018, 00:00

  • PSY19 - USING A BAYESIAN NETWORK META-ANALYSIS (NMA) TO COMPARE FERRIC MALTOL TO TREATMENTS FOR IRON DEFICIENCY AND IRON DEFICIENCY ANAEMIA EXCLUDING CHF AND CKD PATIENTS

    Oct 1, 2018, 00:00

  • PCV48 - TOTAL ANNUAL HEALTHCARE COSTS OF HEART FAILURE BETWEEN 2005 AND 2014- A RETROSPECTIVE, POPULATION-BASED STUDY IN SWEDEN

    Oct 1, 2018, 00:00

  • PHP163 - THE FRENCH HEALTH ECONOMIC RESEARCH PROGRAM(PRME)- AN OVERVIEW SINCE ITS CREATION IN 2013

    Oct 1, 2018, 00:00

  • PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL

    Oct 1, 2018, 00:00

  • PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS’ TREATMENT CHOICE- A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US

    Oct 1, 2018, 00:00

  • PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS - A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEY

    Oct 1, 2018, 00:00

  • PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON

    Oct 1, 2018, 00:00

  • PUK29 - RENAL SEVERITY IN PATIENTS WITH LUPUS NEPHRITIS AT DIAGNOSIS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

    Oct 1, 2018, 00:00

  • PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTS

    Oct 1, 2018, 00:00

  • PDB87 - A COST-OF-CONTROL ANALYSIS- ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAY

    Oct 1, 2018, 00:00

  • PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKING

    Oct 1, 2018, 00:00

  • PSS57 - TREATMENT OF ATOPIC DERMATITIS IN PORTUGAL- INSIGHTS FROM A PHYSICIANS’ SURVEY

    Oct 1, 2018, 00:00

  • PRM11 - A CASE STUDY OF THE IMPACT OF CEESP REVIEWS ON HAS DECISIONS

    Oct 1, 2018, 00:00

  • CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML)- A FRENCH PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING

    Oct 1, 2018, 00:00

  • PHP267 - LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPE

    Oct 1, 2018, 00:00

  • PMH65 - PERSISTENCE WITH SELECTIVE SEROTONIN (NOREPINEPHRINE) REUPTAKE INHIBITOR THERAPY IN GERMANY

    Oct 1, 2018, 00:00

  • PRM50 - IMPROVEMENT OF EFFICIENCY OF SEVERE ATOPIC ASTHMA TREATMENT

    Oct 1, 2018, 00:00

  • PCP39 - INNOVATION IN IDENTIFYING BARRIERS TO ACCESS AND IMPROVING THE QUALITY OF CANCER CARE AND TREATMENT FOR VULNERABLE AREAS PEOPLE, ARGENTINA 2017

    Oct 1, 2018, 00:00

  • PRM127 - ECONOMIC MODELLING CONSIDERATIONS IN RARE DISEASES- A TARGETED REVIEW OF HIGHLY SPECIALISED TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PIN82 - IN SMALL DOSES- MISSING THE BOOSTER DOSE IN A REDUCED PNEUMOCOCCAL CONJUGATE VACCINATION SCHEDULE

    Oct 1, 2018, 00:00

  • PMD175 - MARKET ENTRY OF NEW MEDICAL DEVICES IN GERMANY - OUTPATIENT SECTOR

    Oct 1, 2018, 00:00

  • PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PRS83 - PATIENT PERSPECTIVE ON MEDICATION ADHERENCE IN ASTHMA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS- RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)

    Oct 1, 2018, 00:00

  • PRM118 - ADJUSTMENT FOR SUBSEQUENT THERAPIES RECEIVED- THE IMPACT ON OUTCOMES OF AN ECONOMIC MODEL OF NIVOLUMAB+IPILIMUMAB IN FIRST LINE RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCN282 - CANCER DRUGS FUND (CDF) IN THE UNITED KINGDOM- A 2-YEAR ANALYSIS

    Oct 1, 2018, 00:00

  • PDB5 - EFFECT OF STATINS USAGE ON INCIDENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM111 - APPLICATION AND ACCEPTANCE OF COMPLEX SURVIVAL EXTRAPOLATION METHODS IN HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PRM169 - RESPONSIVENESS OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS FOLLOWING TOTAL HIP OR KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PSY99 - COST-EFFECTIVENESS OF TOCILIZUMAB + PREDNISOLONE COMPARED TO STANDARD OF CARE WITH PREDNISOLONE ALONE IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) IN TURKEY

    Oct 1, 2018, 00:00

  • PIH31 - USE OF ADMINISTRATIVE DATA FOR ASSESSMENT OF MEDICATION PRESCRIPTION PRACTICE IN TWO ITALIAN SETTINGS

    Oct 1, 2018, 00:00

  • PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWS

    Oct 1, 2018, 00:00

  • PRS46 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PSY181 - 2018 UPDATE OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL PSORIASIS AND PSORIATIC ARTHRITIS AGENTS- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTS

    Oct 1, 2018, 00:00

  • PSY5 - PATIENTS WITH RELAPSING ANCA-ASSOCIATED VASCULITIS (AAV) EXPERIENCE UNMET NEEDS AND UTILISE SIGNIFICANT HEALTHCARE RESOURCES

    Oct 1, 2018, 00:00

  • PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PUK33 - COMPARISON OF TREATMENT PATTERN IN UROLITHIASIS - A POPULATION STUDY USING KOREAN HEALTH INSURANCE REVIEW AND ASSESSMENT SERVICE DATABASE

    Oct 1, 2018, 00:00

  • PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS- A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY

    Oct 1, 2018, 00:00

  • PCV57 - HEALTH INSURANCE COST OF HYPERTENSIVE HEART DISEASE IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PCN44 - FIRST-LINE TREATMENT EFFICACY IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY50 - BUDGET-IMPACT ANALYSIS (BIA) OF CHRONIC PAIN SYNDROMES FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIES

    Oct 1, 2018, 00:00

  • PMD101 - COST-EFFECTIVENESS OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN INTERMEDIATE-LOW RISK PATIENTS WITH SEVERE AORTIC STENOSIS IN SINGAPORE

    Oct 1, 2018, 00:00

  • PSS40 - COST-EFFECTIVENESS OF OCRIPLASMIN FOR THE TREATMENT OF VITREOMACULAR TRACTION, INCLUDING WHEN ASSOCIATED WITH MACULAR HOLE- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS- 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?

    Oct 1, 2018, 00:00

  • PRM15 - PRE-APPROVAL SIMULATION OF REAL-WORLD OUTCOMES- DEVELOPMENT OF A METHODOLOGICAL FRAMEWORK

    Oct 1, 2018, 00:00

  • PIN67 - COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINATION IN GERMANY

    Oct 1, 2018, 00:00

  • PMS20 - BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • RM3 - IS PATIENT CHOICE PREDICTABLE? THE IMPACT OF DISCRETE CHOICE EXPERIMENT DESIGNS AND MODELS

    Oct 1, 2018, 00:00

  • PHP158 - DEMAND FOR SECOND OPINIONS IN THE PAEDIATRIC POPULATION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PSY103 - MODELLING AVERAGE COST AND COST-PER-RESPONDER FOR BIOLOGICAL TREATMENTS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS WITH DOSE ESCALATION AND REAL-WORLD DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTS

    Oct 1, 2018, 00:00

  • PMD65 - ECONOMIC VALUE OF NARROW BAND IMAGING VERSUS WHITE LIGHT ENDOSCOPY FOR THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER- COST-CONSEQUENCE MODEL

    Oct 1, 2018, 00:00

  • PSY106 - COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN

    Oct 1, 2018, 00:00

  • PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD135 - DETERMINING FACTORS FOR DECISION-MAKING IN THE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Oct 1, 2018, 00:00

  • PCN213 - FINANCING EXPENSIVE ANTICANCER DRUGS IN HOSPITALS- TOWARDS TRANSPARENCY TO IMPROVE PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTAT

    Oct 1, 2018, 00:00

  • PMD27 - LENS EXPLANTATION AND LENS EXCHANGE RATES WITH MULTIFOCAL IOLS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALY

    Oct 1, 2018, 00:00

  • French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations- The Effect on Patient-Reported Outcomes

    Oct 1, 2018, 00:00

  • PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCER

    Oct 1, 2018, 00:00

  • PRM113 - PREDICTION MODEL FOR IDENTIFYING PATIENTS WITH LIPODYSTROPHY IN ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PSY139 - CURRENT USE OF FACTOR VIII PRODUCTS IN CHILDREN AND ADOLESCENTS WITH MODERATE OR SEVERE HAEMOPHILIA A

    Oct 1, 2018, 00:00

  • PHP102 - ARE SPECIFIC METHODOLOGICAL FRAMEWORKS REQUIRED FOR THE ECONOMIC EVALUATION OF GENE THERAPIES?

    Oct 1, 2018, 00:00

  • PRM23 - MODELLING CANCER TREATMENTS IN THE ADJUVANT SETTING- A TARGETED LITERATURE REVIEW (TLR) OF TECHNOLOGY APPRAISALS (TA) OF ADJUVANT THERAPIES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND A CASE STUDY I ...

    Oct 1, 2018, 00:00

  • PCV146 - SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

    Oct 1, 2018, 00:00

  • PCN8 - SEVERITY OF BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES AND NOT WITH INSULIN TREATMENT

    Oct 1, 2018, 00:00

  • PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UK

    Oct 1, 2018, 00:00

  • PHP157 - APETITE FOR ON PATENTS- COST OF PRESCRIBING SWITCHING IN GREECE

    Oct 1, 2018, 00:00

  • PSY63 - COST BY OUTCOMES ANALYSIS OF NOVEL TRIPLE-COMBINATION THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN BRAZIL

    Oct 1, 2018, 00:00

  • PCN253 - DID THE EUROPEAN FINANCIAL CRISIS HAVE AN IMPACT ON ECONOMIC DECISION-MAKING IN HEALTH TECHNOLOGY ASSESSMENTS?

    Oct 1, 2018, 00:00

  • PMS88 - REAL WORLD PERSISTENCE AND ADHERENCE WITH ORAL BISPHOSPHONATES FOR OSTEOPOROSIS - A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSS2 - VALIDATION STUDY OF AN INFANTILE HEMANGIOMA (IH) SCORING TOOL FOR PRIMARY CLINICIANS TO IDENTIFY PATIENTS REQUIRING REFERRAL TO EXPERT CENTERS

    Oct 1, 2018, 00:00

  • PRM240 - ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY OF ORAL CANCER PATIENTS- INTEGRATION OF LIFETIME SURVIVAL ADJUSTED WITH REPEATED QUALITY OF LIFE MEASUREMENTS

    Oct 1, 2018, 00:00

  • PMD168 - MARKET ACCESS FOR COMPANION DIAGNOSTICS IN ONCOLOGY IN THE EU5 AND ASIA-PACIFIC REGION

    Oct 1, 2018, 00:00

  • ND1 - AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)- THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALS

    Oct 1, 2018, 00:00

  • PSY13 - THE TREATMENT OPTIONS FOR ACUTE ATTACK OF HEREDITARY ANGIOEDEMA (HAE)- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMD20 - COMPARATIVE STUDY OF SPINE ANTERIOR LUMBAR INTERBODY FUSION DEVICES

    Oct 1, 2018, 00:00

  • PHP26 - EVOLUTION OF SICK PAY BENEFITS IN HUNGARY BETWEEN 2005 AND 2016

    Oct 1, 2018, 00:00

  • PRM106 - ADVANCED NMA TECHNIQUES IN NICE HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PIN13 - THE INCIDENCE OF SURGICAL SITE INFECTION IN POLAND

    Oct 1, 2018, 00:00

  • PMS110 - RESEARCH APPLICATIONS OF PATIENT REPORTED OUTCOME MEASURES IN AN ACADEMIC ORTHOPAEDIC SURGERY DEPARTMENT

    Oct 1, 2018, 00:00

  • PRS44 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE- MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

    Oct 1, 2018, 00:00

  • PHP64 - ALLOWABILITY OF OUTCOMES-BASED RISK-SHARING SCHEMES IN RUSSIA WITHIN CURRENT LEGISLATIVE HURDLES

    Oct 1, 2018, 00:00

  • PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOL

    Oct 1, 2018, 00:00

  • PMU110 - EXPLORING U.S. CONSUMERS’ KNOWLEDGE, ATTITUDES AND PRACTICES TOWARDS OVER-THE-COUNTER MEDICATIONS

    Oct 1, 2018, 00:00

  • PHP161 - ASSESSING THE NET PRICE LEVEL OF GENERICS IN GREECE- THE EFFECT OF COMPULSORY PAYBACKS

    Oct 1, 2018, 00:00

  • PMH55 - A COMPARISON OF PATIENTS PRESCRIBED ANTIPSYCHOTICS FOR PARKINSON’S DISEASE WITH PSYCHOSIS USING ADMINISTRATIVE CLAIMS DATA FROM A LARGE U.S. INSURER

    Oct 1, 2018, 00:00

  • PMU126 - SUBJECTIVE EXPECTATIONS REGARDING FUTURE HEALTH, WELL-BEING AND HEALTHCARE COSTS IN HUNGARY

    Oct 1, 2018, 00:00

  • PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING- A RETROSPECTIVE STUDY

    Oct 1, 2018, 00:00

  • PRM35 - INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?

    Oct 1, 2018, 00:00

  • PIN55 - COST-EFFECTIVENESS ANALYSIS OF INFANT FORMULA SUPPLEMENTED WITH HUMAN MILK OLIGOSACCHARIDE (HMO) IN THE PREVENTION OF LOWER RESPIRATORY TRACT INFECTIONS IN MEXICO AND CHINA

    Oct 1, 2018, 00:00

  • PIH26 - PRACTICE TOWARD ANTIBIOTICS PREPARATION AMONG IRANIAN PARENTS

    Oct 1, 2018, 00:00

  • PRM97 - PATIENT VERSUS TREATMENT LINE LEVEL MATCHING- IMPACT ON COVARIATES BALANCE AND COST EFFECTIVENESS RESULTS, A CASE STUDY IN ONCOLOGY

    Oct 1, 2018, 00:00

  • Assessing Rationality in Discrete Choice Experiments in Health- An Investigation into the Use of Dominance Tests

    Oct 1, 2018, 00:00

  • PMS103 - IMPACT OF PHYSICAL FUNCTIONING ON THE QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD182 - DISCRETE CHOICE EXPERIMENTS TO MEASURE PATIENTS' PREFERENCES FOR CORONARY REVASCULARIZATION.

    Oct 1, 2018, 00:00

  • PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM

    Oct 1, 2018, 00:00

  • PSY96 - COST-EFFECTIVENESS OF ORIGINATOR ADALIMUMAB IN NON-INFECTIOUS INTERMEDIATE, POSTERIOR AND PAN-UVEITIS FROM A SOCIETAL PERSPECTIVE IN PORTUGAL

    Oct 1, 2018, 00:00

  • PIN116 - PRIORITIZING INVESTMENTS IN NEW VACCINES AGAINST EPIDEMIC INFECTIOUS DISEASES- A MULTI-CRITERIA DECISION ANALYSIS

    Oct 1, 2018, 00:00

  • PND4 - CLOBAZAM AS INTERMITENT PROPHYLAXIS IN TYPICAL FEBRILE SEIZURES AND THEIR ANEMIC STATUS

    Oct 1, 2018, 00:00

  • PMS81 - CONSENSUS ON THE MEASUREMENT INSTRUMENTS TO EVALUATE THE EFFECTIVENESS OF BIOLOGICAL TREATMENT IN PSORIATIC ARTHRITIS- MERECES STUDY.

    Oct 1, 2018, 00:00

  • PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

    Oct 1, 2018, 00:00

  • PDB106 - ASSESSING THE HEALTH AND ECONOMIC IMPACT OF PHARMACEUTICAL CARE IN ELDERLY PATIENTS WITH DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN201 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMU75 - IS ADOPTING A LOW PRICE STRATEGY TO GAIN MARKET ACCESS COMPATIBLE WITH A VIABLE GENE/CELL THERAPY BUSINESS?

    Oct 1, 2018, 00:00

  • PMH3 - COMPARING THE RISK OF SUICIDALITY IN ADULT VERSUS YOUTH PATIENTS TREATED WITH SEROTONIN REUPTAKE INHIBITORS - A REAL-WORLD EVIDENCE-BASED APPROACH

    Oct 1, 2018, 00:00

  • PCV21 - IMPACT OF GENETIC AND NON-GENETIC FACTORS ON CLOPIDOGREL EFFICACY

    Oct 1, 2018, 00:00

  • PCV123 - ECONOMIC EVALUATION FOR ROSUVASTATIN VS. ATORVASTATIN IN EGYPTIAN PATIENTS WITH HYPERLIPIDEMIA EGYPT CASE

    Oct 1, 2018, 00:00

  • PSY90 - RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE DATA TO ASSESS ADHERENCE, PHARMACOUTILIZATION AND COSTS OF BIOLOGICAL THERAPY TREATMENT OF PSORIASIS IN SOUTHERN ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PCN42 - EFFICACY OF THIRD LINE TYROSINE KINASE INHIBITORS FOR TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOURS- SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERA

    Oct 1, 2018, 00:00

  • PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCN54 - IN-HOSPITAL RESOURCE USE FOR CANCER IN GERMANY FROM 2010 TO 2015

    Oct 1, 2018, 00:00

  • PMU52 - COST IN COMPLEX ABDOMINAL OPERATIONS IN PUBLIC HEALTH INSURANCE PERSPECTIVE FOR TURKEY

    Oct 1, 2018, 00:00

  • PMU38 - REVIEW OF STUDIES REPORTING ACTUAL PRICES FOR MEDICINES

    Oct 1, 2018, 00:00

  • PSY66 - AN EFFICIENT AMBULATORY SERVICE MODEL FOR HEMOPHILIC PATIENTS, A COST-BENEFIT APPROACH

    Oct 1, 2018, 00:00

  • PRM248 - REFERENCED-BASED IMPUTATION FOR THE COST-EFFECTIVENESS ANALYSIS OF LONGITUDINAL RANDOMISED TRIAL

    Oct 1, 2018, 00:00

  • PHP37 - SPEEDING TO MARKET? AN EVALUATION OF ACCELERATED DRUG APPROVAL PATHWAYS IN AUSTRALIA, CANADA, AND SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PSY189 - TREATMENT GUIDELINE INCLUDING THE HEALTH ECONOMIC EVALUATIONS OF BIOLOGIC DRUGS USED FOR PSORIATIC ARTHRITIS- PICOSTEPS, SYSTEMATIC LITERATURE REVIEW, APPLICABILITY EVALUATION AND LEVEL OF EVIDENCE EVALUATION

    Oct 1, 2018, 00:00

  • PMH7 - DURATION OF INABILITY TO WORK IN DEPRESSION PATIENTS TREATED IN GENERAL OR PSYCHIATRIC PRACTICES IN GERMANY

    Oct 1, 2018, 00:00

  • PSY14 - CLINICAL RESPONSE TO SYSTEMIC TREATMENTS FOR STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP331 - IS IT ENOUGH TO HAVE IT IN THE VACCINATION PROGRAMME? AN EMPIRICAL ANALYSIS OF THE FACTORS THAT AFFECT INFLUENZA VACCINATION UPTAKE IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • PHP70 - COUNTRY-SPECIFIC DRIVERS AND BARRIERS FOR MARKET ACCESS OF E-HEALTH SOLUTIONS

    Oct 1, 2018, 00:00

  • PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP182 - EXTERNAL REFERENCE PRICING- CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVER

    Oct 1, 2018, 00:00

  • PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMD4 - SYSTEMATIC REVIEW AND META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES- FLUORESCENCE ENZYME IMMUNOASSAY VERSUS INDIRECT IMMUNOFLUORESCENT ASSAYS FOR INITIAL SCREENING FOR CONNECTIVE TISSUE DISEASES

    Oct 1, 2018, 00:00

  • PHP146 - ANALYSES OF THE PERFORMANCE INDICATORS OF REHABILITATION AND CHRONIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2016

    Oct 1, 2018, 00:00

  • PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENT

    Oct 1, 2018, 00:00

  • PIN87 - PHYSICIAN PREFERENCES FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION- AN ADAPTIVE CONJOINT ANALYSIS

    Oct 1, 2018, 00:00

  • PIN2 - IMPACT OF ADHERENCE TO HEDIS MEASURES ON THE QUALITY OF CARE FOR PEDIATRIC PATIENTS WITH PHARYNGITIS- EVIDENCE FROM A LARGE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PMS95 - DO DISAGREEMENTS BETWEEN PATIENT AND POPULATION VALUATIONS DIFFER BY SOCIO-DEMOGRAPHIC GROUP AND/OR HEALTH STATUS? AN EXPLORATORY STUDY AMONG CHRONIC LOW BACK PAIN PATIENTS

    Oct 1, 2018, 00:00

  • PMD50 - MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND VERSUS DEEP BRAIN STIMULATION IN MEDICALLY-REFRACTORY ESSENTIAL TREMOR- A COST-CONSEQUENCE ANALYSIS IN THE UK SETTING

    Oct 1, 2018, 00:00

  • PHP47 - EVALUATING PATIENTS’, PHYSICIANS’ AND PHARMACISTS’ PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIA

    Oct 1, 2018, 00:00

  • PRM49 - MEASUREMENT AND VALUATION OF PRODUCTIVITY IN HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PCV151 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH HEART FAILURE? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PSY191 - HEALTH STATE UTILITIES ASSOCIATED WITH TREATMENT FOR TRANSFUSION DEPENDENT B-THALASSEMIA

    Oct 1, 2018, 00:00

  • PRM226 - DEVELOPMENT OF A METHOD FOR A STAR-SHAPED NETWORK META-ANALYSIS UNDER UNIDENTIFIABLE CONSISTENCY ASSUMPTION

    Oct 1, 2018, 00:00

  • PMD136 - THE FEASIBILITY OF APPLYING THE MULTIPLE CRITERIA DECISION ANALYSIS FOR THE EVALUATION OF MEDICAL DEVICES IN THE CONTEXT OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT IN TURKEY

    Oct 1, 2018, 00:00

  • PRM147 - OPEN-SOURCE MODELS IN HEALTH ECONOMICS- EXPERIENCE BASED ON A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PDB121 - QUALITY OF LIFE AND UTILITY VALUES FOR COST-EFFECTIVENESS MODELING IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH- WHAT CAN BE LEARNED?

    Oct 1, 2018, 00:00

  • PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PRS61 - ASSESSMENT OF ASTHMA-DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY IN VENETO REGION

    Oct 1, 2018, 00:00

  • AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY- APPROVAL CONDITIONS (2015-2018)

    Oct 1, 2018, 00:00

  • PRM193 - FROM INDIVIDUAL PATIENT TO POPULATION PREFERENCES- MULTINOMIAL LOGIT MODEL VS DIRICHLET DISTRIBUTION

    Oct 1, 2018, 00:00

  • PMD18 - IMPACT OF DIFFERENT IOL MATERIALS ON THE INCIDENCE OF ND-YAG LASER CAPSULOTOMY- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PIH13 - ABIRATERONE- A SINGLE-CENTRE EXPERIENCE

    Oct 1, 2018, 00:00

  • PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).

    Oct 1, 2018, 00:00

  • PSY58 - BUDGET IMPACT ANALYSIS OF EMICIZUMAB IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS IN THE MINISTRY OF HEALTH (MOH), KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PCN40 - A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE + PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARK

    Oct 1, 2018, 00:00

  • PRM109 - EXPLORING THE USE AND ACCEPTANCE OF ALTERNATIVE SURVIVAL MODELLING APPROACHES FOR IMMUNO-ONCOLOGY THERAPIES IN UK TECHNOLOGY ASSESSMENTS

    Oct 1, 2018, 00:00

  • PIH38 - PREVALENCE OF PELVIC FLOOR DISORDERS AMONG WOMEN IN EASTERN REGION OF NEPAL

    Oct 1, 2018, 00:00

  • PSS32 - COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PMS121 - EVALUATION OF THE WORK PRODUCTIVITY IN ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) PATIENTS BEFORE AND AFTER THE START OF ADALIMUMAB THERAPY IN DAILY PRACTICE IN BELGIUM (SPACTIVE STUDY)

    Oct 1, 2018, 00:00

  • PGI30 - POLISH THERAPEUTIC ALGORITHMS IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

    Oct 1, 2018, 00:00

  • PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

    Oct 1, 2018, 00:00

  • PHP346 - THE EVOLUTION FROM INTEREST TO EXECUTION- AN ANALYSIS OF RECENT TRENDS IN OUTCOMES BASED CONTRACTING ACROSS THE US AND EU

    Oct 1, 2018, 00:00

  • PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE- THE TG-REAL STUDY

    Oct 1, 2018, 00:00

  • PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSIS

    Oct 1, 2018, 00:00

  • PMU106 - CHOOSING VIDEO INSTEAD OF IN-CLINIC CONSULTATIONS IN PRIMARY CARE- DISCRETE CHOICE EXPERIMENT AMONG KEY STAKEHOLDERS- PATIENTS, PRIMARY CARE PRACTITIONERS AND POLICY MAKERS

    Oct 1, 2018, 00:00

  • PIN24 - ESTIMATION OF HOSPITAL COST SAVINGS ASSOCIATED WITH HYPOTENSION REDUCTION IN SEPTIC INTENSIVE CARE UNIT PATIENTS IN US HOSPITALS

    Oct 1, 2018, 00:00

  • PRS21 - ECONOMIC IMPACT OF DELAYING INITIATION WITH MULTIPLE INHALER MAINTENANCE TRIPLE THERAPY TREATMENT IN SPANISH COPD PATIENTS

    Oct 1, 2018, 00:00

  • PCN55 - TYPE-SPECIFIC DATA ON HUMAN PAPILLOMAVIRUS INFECTION IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA IN THE ASIA-PACIFIC REGION

    Oct 1, 2018, 00:00

  • PRM276 - METHODOLOGICAL ISSUES OF DRUG PRICE COMPARISON STUDIES- WHAT IMPROVEMENT IN QUALITY?

    Oct 1, 2018, 00:00

  • PCN18 - TREATMENT OF POST-MENOPAUSAL ADVANCED BREAST CANCER- NETWORK META-ANALYSIS USING SECOND-ORDER FRACTIONAL POLYNOMIALS MODELS

    Oct 1, 2018, 00:00

  • PRM91 - DATA-DRIVEN AND INSIGHTFUL- AN ANALOGUE ANALYSIS TOOL FOR RAPID AND TARGETED PRICING EXPLORATION

    Oct 1, 2018, 00:00

  • PIN105 - THE PUBLIC HEALTH IMPACT OF TICK-BORNE ENCEPHALITIS VACCINATION ON THE SLOVENIAN ADULT POPULATION

    Oct 1, 2018, 00:00

  • PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE- AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PMS52 - COST-EFFECTIVENESS ANALYSIS OF TELEREHABILITATION FOR POST-ACUTE HIP ARTHROPLASTY- A DECISION MODEL

    Oct 1, 2018, 00:00

  • PDB88 - ADVENT OF MOBILE PLATFORMS LEVERAGES MULTISTAKEHOLDER COLLABORATION TO DRIVE OUTCOMES IN DIABETES

    Oct 1, 2018, 00:00

  • PCV11 - MODELING CARDIOVASCULAR EVENT REDUCTION THROUGH LOW-DENSITY LIPOPROTEIN REDUCTION IN COST-EFFECTIVENESS ANALYSES- A META-REGRESSION APPROACH

    Oct 1, 2018, 00:00

  • PIN40 - COST-EFFECTIVENESS OF FIRST-LINE TREATMENT FOR INVASIVE ASPERGILOSIS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PSY10 - PATIENT CHARACTERISTICS AND IN-HOSPITAL MANAGEMENT OF EPISODES OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA- A FRENCH REAL-LIFE POPULATION BASED STUDY

    Oct 1, 2018, 00:00

  • PIH39 - THE ASSOCIATION BETWEEN THE DIFFICULTIES IN THE ENTRANCE EXAM FOR MEDICAL UNIVERSITY AND PHYSICIANS' CAREER CHOICE- EVIDENCE FROM JAPAN

    Oct 1, 2018, 00:00

  • PRM187 - A SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN MELANOMA IN THE ADJUVANT SETTING

    Oct 1, 2018, 00:00

  • PMD19 - EFFECTIVENESS OF REAL-TIME POLYMERASE CHAIN REACTION FOR THE DIAGNOSIS AND MONITORING OF ADENOVIRUS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICS

    Oct 1, 2018, 00:00

  • PSY161 - A RAPID LITERATURE REVIEW OF REAL-WORLD EVIDENCE IN MULTIPLE MYELOMA- PATIENT CHARACTERISTICS AND HEALTH OUTCOMES

    Oct 1, 2018, 00:00

  • PDB81 - DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCN358 - SATISFACTION WITH HEALTH CARE ANALYSIS IN CERVIX-UTERI CANCER MEXICAN WOMEN TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PDB51 - RESULTS OF THE COSMODIA STUDY- ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN ...

    Oct 1, 2018, 00:00

  • PHP126 - SCARS OF CHILD POVERTY IN ADULTS- A HEALTH PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD53 - REMOVABLE DINOPROSTONE VAGINAL DELIVERY SYSTEM- COST-CONSEQUENCES MODEL FOR CENTRAL AND EASTERN EUROPE COUNTRIES

    Oct 1, 2018, 00:00

  • PSY42 - EXPLORING THE POTENTIAL BUDGET IMPACT OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

    Oct 1, 2018, 00:00

  • CV2 - IMPACT OF ATRIAL FIBRILLATION (AF) AWARENESS CAMPAIGNS ON RATES OF AF RELATED CONSULTATIONS IN UK PRIMARY CARE- INTERRUPTED TIME SERIES ANALYSES.

    Oct 1, 2018, 00:00

  • PCN351 - HEALTH-STATE UTILITY VALUES IN DIFFUSE LARGE B-CELL LYMPHOMA

    Oct 1, 2018, 00:00

  • PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PMD66 - COMPARING THE LONG-TERM IMPACT ON HEALTHCARE RESOURCES AND COSTS DUE TO SINGLE-PIECE ACRYLIC INTRAOCULAR LENS (IOLS) IMPLANTATION DURING CATARACT SURGERY- A COST-CONSEQUENCE ANALYSIS FROM UK HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN184 - COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

    Oct 1, 2018, 00:00

  • PCN111 - COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMA

    Oct 1, 2018, 00:00

  • PSY202 - THE OCCUPATIONAL HAZARDS OF MEASURING RISK TOLERANCE- CONVERGENT VALIDITY IN PREFERENCE ELICITATION.

    Oct 1, 2018, 00:00

  • PMH15 - A NETWORK META-ANALYSIS OF MEDICINES USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS

    Oct 1, 2018, 00:00

  • PMD69 - SYSTEMATIC REVIEW AND ECONOMIC ANALYSIS OF ANTISEPTIC BARRIER CAPS IN PATIENTS WITH CENTRAL OR PERIPHERAL LINE CATHETERS

    Oct 1, 2018, 00:00

  • PUK2 - PREDICTORS FOR BLOOD PRESSURE CONTROL AMONG POST DIALYSIS HYPERTENSIVE PATIENTS WHEN TREATED WITH AND WITHOUT RAAS INHIBITOR

    Oct 1, 2018, 00:00

  • PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMAB

    Oct 1, 2018, 00:00

  • PCV86 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA- PERCEPTIONS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PIN43 - A COST-EFFECTIVENESS ANALYSIS OF REVACCINATING OLDER ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO VACCINATING WITH A SINGLE DOSE OF PPV23 IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PRM61 - LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMS102 - THE RELATION BETWEEN TRAINING METHODS AND FORMED INJURIES AMONG PEOPLE DOING WEIGHT TRAINING

    Oct 1, 2018, 00:00

  • PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA

    Oct 1, 2018, 00:00

  • PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMES

    Oct 1, 2018, 00:00

  • PMS27 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PRM78 - TECHNIQUES FOR PREVENTION AND DETECTION OF FRAUD IN RANDOMISED CONTROLLED TRIALS BASED ON ROUTINELY COLLECTED ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PMS30 - COST ANALYSIS FOR DIFFERENT ANTI-RHEUMATOID BIOLOGICAL TREATMENTS AFTER FAILURE OF CONVENTIONAL DMARDS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS?

    Oct 1, 2018, 00:00

  • PHP369 - CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE- A CASE STUDY

    Oct 1, 2018, 00:00

  • PSS1 - SYSTEMATIC REVIEWS OF OPHTHALMIC ADVERSE DRUG REACTIONS PUBLISHED IN OPHTHALMOLOGY JOURNALS- A METHODOLOGICAL ASSESSMENT

    Oct 1, 2018, 00:00

  • PHP269 - DESIGN AND EVALUATION OF MALAYSIAN MODEL OF PHARMACEUTICAL PICTOGRAMS

    Oct 1, 2018, 00:00

  • PSS72 - FAMILY PSO- IMPACT OF PSORIASIS ON THE PARTNER

    Oct 1, 2018, 00:00

  • PHP234 - EVALUATING THE IMPACT OF VALUE BASED PRICING (VBP) AND HTA ON PRICE LEVELS IN AN EU CONTEXT

    Oct 1, 2018, 00:00

  • PIN42 - DETERMINATING THE ACCEPTABLE PRICE FOR QUADRIVALENT INFLUENZA VACCINE IN RUSSIA

    Oct 1, 2018, 00:00

  • PSY165 - PRICE DIFFERENCES FOR ORPHAN DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PSY214 - PHYSICAL ACTIVITY AND QUALITY OF LIFE OUTCOMES IN MULTIPLE MYELOMA PATIENTS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PIN14 - BIOMEDICAL AND THERAPEUTIC PREDICTORS OF SURVIVAL TIME AND MORTALITY OF ADULT HIV/TB CO-INFECTIONS; A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PND85 - PROPHYLACTIC MIGRAINE MEDICATION USE IN PRIMARY CARE SETTING IN FINLAND

    Oct 1, 2018, 00:00

  • PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELING

    Oct 1, 2018, 00:00

  • PMU21 - ROLE OF PHARMACISTS FROM RESEARCH TO HEALTHCARE- AN IGNORE PARADIGM IN LOWER INCOME COUNTRY COUNTRY

    Oct 1, 2018, 00:00

  • PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

    Oct 1, 2018, 00:00

  • PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES- IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENT

    Oct 1, 2018, 00:00

  • PRS99 - IMPACT OF COUGH AND MUCUS ON THE EMOTIONAL AND PSYCHOSOCIAL WELLBEING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE- A QUALITATIVE PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018)- NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORT

    Oct 1, 2018, 00:00

  • PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?

    Oct 1, 2018, 00:00

  • PND76 - THE ECONOMIC CONSEQUENCES OF BENEFITS OF DELAYED-RELEASE DIMETHYL FUMARATE TREATMENT VERSUS BETA INTERFERONS AND GLATIRAMER ACETATE ON ABILITY TO WORK OF MULTIPLE SCLEROSIS PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION- REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAEL

    Oct 1, 2018, 00:00

  • PMD93 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TYPES OF MONOFOCAL INTRAOCULAR LENSES FOR CATARACT SURGERY IN RUSSIA

    Oct 1, 2018, 00:00

  • PSY56 - COST-UTILITY OF NEW FILM-COATED TABLET FORMULATION OF DEFERASIROX VERSUS DEFEROXAMINE AMONG MAJOR B-THALASSEMIA PATIENTS IN IRAN

    Oct 1, 2018, 00:00

  • PMS118 - QUALITY OF LIFE OF DUPUYTREN’S DISEASE PATIENTS TREATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM- A PROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PIN9 - NOVEL APPROACH FOR INFLUENZA VACCINATION- APPLICATION OF AN EMERGING TECHNOLOGIES EVALUATION STRATEGY

    Oct 1, 2018, 00:00

  • PMD176 - MEDICATION ADHERENCE ASCERTAINED BY A DIGITAL OBSERVATIONAL STUDY APPROACH USING A MEDICAL APP- A PILOT STUDY AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA-1B

    Oct 1, 2018, 00:00

  • PRM214 - DO UTILITY VALUES USED IN HEALTH TECHNOLOGY ASSESSMENT MAINLY COME FROM WIDELY CITED REFERENCES?

    Oct 1, 2018, 00:00

  • PCN195 - COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAIN

    Oct 1, 2018, 00:00

  • PCN279 - A REVIEW OF RECOMMENDATIONS FOR INCLUSION AND DATA COLLECTION WITHIN THE CDF FRAMEWORK

    Oct 1, 2018, 00:00

  • PIN74 - A SYSTEMATIC REVIEW ON ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION

    Oct 1, 2018, 00:00

  • PMU61 - BEYOND THE COST-EFFECTIVENESS ACCEPTABILITY CURVE- THE APPROPRIATENESS OF RANK PROBABILITIES FOR PRESENTING THE RESULTS OF ECONOMIC EVALUATION IN MULTIPLE TECHNOLOGY APPRAISAL

    Oct 1, 2018, 00:00

  • PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAEL

    Oct 1, 2018, 00:00

  • PCN373 - UNDERSTANDING PATIENT PERSPECTIVES OF RENAL CELL CARCINOMA USING SOCIAL MEDIA- A QUALITATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PMU113 - TIME-DEPENDENT VARIATION OF PRO SCORES IN CHRONIC CONDITIONS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PRM177 - CAN THE EQ-5D HELP UNDERSTAND HOW CHANGES IN CLINICAL OUTCOMES IMPACT ON DIFFERENT CONCEPTS OF HEALTH?

    Oct 1, 2018, 00:00

  • PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS- A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.

    Oct 1, 2018, 00:00

  • PMD103 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING LEG ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION- ERLOTINIB RENEGOTIATION IN ITALY

    Oct 1, 2018, 00:00

  • PSY205 - BODY IMAGE IN SLE AND THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND PSYCHOSOCIAL CONCERNS

    Oct 1, 2018, 00:00

  • PRM64 - THE NEED FOR INNOVATIVE SURVIVAL MODELLING APPROACHES IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) OF EARLY-STAGE ONCOLOGY INDICATIONS

    Oct 1, 2018, 00:00

  • PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS- EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTS

    Oct 1, 2018, 00:00

  • PDB42 - PRICE ANALYSIS OF ANTIDIABETIC DRUGS MARKETED IN ARABIC COUNTRIES

    Oct 1, 2018, 00:00

  • PRS80 - HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL ASTHMA THERAPIES- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • PRM136 - A PILOT OF ONLINE SURVEY SOFTWARE FOR EXPERT ELICITATION AT NICE

    Oct 1, 2018, 00:00

  • AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Oct 1, 2018, 00:00

  • PCN363 - A BEST–WORST SCALING SURVEY OF PREFERENCES OF CURRENT, PAST AND NEVER SMOKERS FOR ADVERSE EFFECTS OF SMOKING IN JAPAN

    Oct 1, 2018, 00:00

  • PND34 - PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Oct 1, 2018, 00:00

  • PMD42 - ECONOMIC IMPACT OF LAPAROSCOPIC VS OPEN SURGERY FOR COLORECTAL CANCER- A BUDGET IMPACT ANALYSIS IN ITALY

    Oct 1, 2018, 00:00

  • PMU119 - PATIENT PREFERENCES IN THE TREATMENT OF PERIODONTAL DISEASE- A LATENT CLASS ANALYSIS

    Oct 1, 2018, 00:00

  • PMU76 - PATIENT SATISFACTION FROM INSTRUCTIONS OF COLONOSCOPY PREPARATION AND COST ASSESSMENT OF INADEQUATE BOWEL PREPARATION

    Oct 1, 2018, 00:00

  • PSY164 - DRIVERS OF ORPHAN MEDICINAL PRODUCT VALUE, PRICE AND COSTS – A PRACTICAL EXPLORATORY ANALYSIS

    Oct 1, 2018, 00:00

  • PMD28 - VAGUS NERVE STIMULATION FOR TREATMENT-RESISTANT DEPRESSION- A BUDGET IMPACT ANALYSIS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMD58 - A PROSPECTIVE, RANDOMIZED TIME-AND-MOTION STUDY COMPARING RATE OF PROCESSING TECHNIQUES IN AUTOLOGOUS FAT GRAFTING- AN ECONOMIC ANALYSIS

    Oct 1, 2018, 00:00

  • PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN2 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC MELANOMA- PRELIMINARY RESULTS FROM REAL WORLD

    Oct 1, 2018, 00:00

  • PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREA

    Oct 1, 2018, 00:00

  • PCN336 - TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRS12 - DEVELOPMENT AND VALIDATION OF AN ALGORITHM IDENTIFYING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN HOSPITAL DISCHARGE DATABASES

    Oct 1, 2018, 00:00

  • PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PMS90 - A BONE RESORPTION MARKER TO MONITOR DRUG PROFILE IN PATIENTS WITH OSTEOPOROTIC FRACTURES

    Oct 1, 2018, 00:00

  • PCV142 - ADHERENCE TO ORAL ANTICOAGULATION TREATMENT IN ATRIAL FIBRILLATION AND THE IMPACT OF PATIENT SATISFACTION

    Oct 1, 2018, 00:00

  • PSY9 - REAL-WORLD EPIDEMIOLOGY, TREATMENT PATTERNS AND SURVIVAL OF MULTIPLE MYELOMA PATIENTS IN A LARGE NATIONWIDE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS- A POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE- A CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKS

    Oct 1, 2018, 00:00

  • PND2 - RISK OF PARKINSON’S DISEASE (PD) IN PATIENTS TAKING ADRENERGIC DRUG TREATMENTS

    Oct 1, 2018, 00:00

  • PHP287 - GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONS

    Oct 1, 2018, 00:00

  • PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP89 - CLASS CNN DRUGS IN ITALY- PURCHASE AND PRESCRIPTION BEHAVIOR IN ITALIAN HOSPITALS

    Oct 1, 2018, 00:00

  • PHP358 - TIME-LIMITED G-BA RESOLUTIONS – A TOOL TO APPROPRIATELY MANAGE REIMBURSEMENT OF INNOVATIVE THERAPIES RECEIVING EXPEDITED REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PSS52 - THE BURDEN IN DIABETIC MACULAR EDEMA IN KOREA

    Oct 1, 2018, 00:00

  • PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM58 - IMPACT OF FUTURE COSTS IN COST-EFFECTIVENESS ANALYSES AND A COMPARISON OF DIRECT AND INDIRECT METHODS USING MODELS OF CABAZITAXEL IN PROSTATE CANCER AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME

    Oct 1, 2018, 00:00

  • PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTING

    Oct 1, 2018, 00:00

  • PRM172 - LEARNINGS ON BRING YOUR OWN DEVICE UPTAKE FOR ECOA IMPLEMENTATION- A TALE OF TWO STUDIES

    Oct 1, 2018, 00:00

  • PSY186 - CREATING AND MAINTAINING THE BULGARIAN CYSTIC FIBROSIS REGISTRY – NOT REALLY A MISSION IMPOSSIBLE

    Oct 1, 2018, 00:00

  • PMD83 - CERVICAL CANCER SCREENING IN EUROPE - A SYSTEMATIC REVIEW ON COST EFFECTIVENESS STUDIES WITH SPECIFIC INTEREST ON RISK-ADAPTED STRATEGIES

    Oct 1, 2018, 00:00

  • PCN129 - TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PSY77 - ASSESSING THE IMPACT OF FORTIFYING PACKAGED INFANT CEREALS IN REDUCING THE BURDEN OF IRON DEFICIENCY ANEMIA IN PAKISTAN

    Oct 1, 2018, 00:00

  • PHP305 - CONSIDERING CHILDREN ALONGSIDE ADULTS IN NICE TECHNOLOGY APPRAISALS AND HIGHLY SPECIALISED TECHNOLOGIES EVALUATIONS

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66 (current)
  • 67
  • 68
  • 69
  • 70
  • »